BPC-157 + AOD-9604 Stack: Evidence, Mechanism Overlap, and Protocol

Does the Stack Have Any Human Evidence?

No. The evidence that exists is separate for each peptide. AOD-9604's largest human test was an oral anti-obesity drug candidate that did not meet its primary endpoint and was later dropped [2]. The BPC-157 human studies are summarized below.

What the Two Peptides Are

BPC-157 is a synthetic 15-amino-acid peptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val and a molecular weight of about 1419.5 g/mol, described as a fragment of a protein first isolated from human gastric juice. It is made as a free base or as an acetate salt, and FDA treats those as two different bulk substances [1].

AOD-9604 is human growth hormone amino acids 177 to 191 with an extra tyrosine added at the N-terminus, giving 16 amino acids (a hexadecapeptide) and the alternate name hGH fragment 176-191. It is not full-length growth hormone [3][2]. An Australian company, Metabolic Pharmaceuticals, developed it as an anti-obesity candidate, with phase IIa trials underway by February 2002 [4]. It never reached approval, and the obesity program was later dropped [2].

Mechanism: Do the Two Overlap?

Not in any documented way. The two peptides are not described as acting on a common receptor.

BPC-157

In a July 2026 review of BPC-157 for ulcerative colitis, FDA's own reviewers wrote that its molecular targets have not been identified, that its mechanisms remain poorly understood, and that dose-response relationships for the protective effects credited to it were never established [1]. Those protective effects, such as preventing colonic fistulas and liver or gut lesions, come from rat studies rather than human trials [1]. A 2016 review from the Sikiric group lists Egr-1, NAB2, FAK-paxillin and JAK-2 pathways as implicated in its effects [9].

AOD-9604

The AOD-9604 case rests on rodent work. In obese Zucker rats given 500 micrograms/kg/day by mouth for 19 days, body-weight gain was 15.8 g versus 35.6 g in controls, fat-tissue lipolytic activity rose, and insulin sensitivity was not impaired on euglycemic clamp testing [10]. In obese mice, 14 days of intraperitoneal growth hormone or AOD-9604 reduced body weight and body fat and raised beta-3 adrenergic receptor RNA; mice lacking that receptor did not show the long-term weight and lipolysis changes [11]. That study's own conclusion was that the lipolytic actions of both compounds are not mediated directly through the beta-3 receptor, though both raise receptor expression [11]. A 2026 review adds that preclinical work found no growth-hormone-receptor binding [2].

AOD-9604: What the Human Data Show

The main human test was a 24-week study of AOD9604 as an oral anti-obesity drug candidate, and it did not show a significant benefit on the primary weight-loss endpoint. That conclusion rests on sponsor-reported phase 2 results rather than peer-reviewed randomized trials, and no peer-reviewed efficacy paper for the trial was found [2]. The same review states there are no robust human data for visceral-fat reduction or other metabolic benefit [2].

Human data on IGF-1 and body composition are too limited to say anything beyond that [2]. The claim that AOD-9604 repairs joints rests on a rabbit knee osteoarthritis study of intra-articular AOD9604 with or without hyaluronic acid; no convincing human osteoarthritis trial exists [12][2].

BPC-157: What the Human Data Show

A systematic review searched to June 1, 2026 found three eligible human studies with 30 patients in total, all of poor methodological quality, with overall certainty of evidence rated very low. The reviewers concluded BPC-157 should not be used clinically outside ethically approved, high-quality trials [5].

The three studies were a retrospective chart review at one Florida clinic, in which 16 of 17 patients were contacted and 11 of the 12 who received BPC-157 alone reported significant improvement, with no control group and no validated outcome tools [13]; a single-arm pilot in 12 women with interstitial cystitis who received 10 mg injected around the bladder wall, of whom 10 reported complete symptom resolution and 2 about 80 percent, all patient-rated [14]; and a two-person intravenous pilot using 10 mg on day one and 20 mg on day two, which found no measurable change in the tested heart, liver, kidney, thyroid or glucose markers [15].

The BPC-157 ulcerative colitis trial FDA reviewed was published only as a conference abstract (Gastroenterology 128:A584): 53 people with mild to moderate disease were randomized to an 80 mg enema or placebo daily for two weeks. FDA said the abstract carries too little detail to judge effectiveness [1].

Dosing: What Is Actually Documented

Neither peptide has an approved dose, because neither is an approved product [1][2].

For BPC-157, the doses that appear in the small human reports are a rectal enema of up to 2 mg/kg daily for 8 days in healthy volunteers and 80 mg daily for 2 weeks in ulcerative colitis, 2 to 4 mg injected into the knee once or twice, 10 mg injected into the bladder wall once, and 10 mg followed by 20 mg intravenously on two days in two healthy adults. None of these is a recommended dose [1].

For AOD-9604, the only sizeable human study tested an oral drug candidate [2]. The injectable forms sold online have no efficacy trials that we found [2].

Safety and Tolerability

BPC-157: FDA concluded there is insufficient clinical safety information to characterize its safety profile, and found no human studies of BPC-157 given by mouth, by subcutaneous injection, by nasal spray or on the skin [1]. Its search of the adverse-event database through December 4, 2025 turned up three reports, all for injectable product: injection-site redness and swelling lasting nine days in a patient who also used compounded thymosin; shortness of breath leading to an emergency room visit; and widespread skin and gum darkening that recurred when the patient was re-exposed to a BPC-157 plus TB-500 research product. FDA said it cannot tell whether BPC-157 caused any of them [1]. Animal signals noted by FDA include shortened clotting time (aPTT) in rats and prolonged aPTT in dogs in 28-day intramuscular studies, plus raised ALT, glucose and triglyceride levels; longer studies and cancer-risk studies were not available [1].

AOD-9604: FDA states it has identified serious adverse events that may be associated with AOD-9604, though causality is not clear, and gives no details [16]. A 2026 review concludes that human evidence is limited and largely short-term [2].

FDA's stated concerns about compounding either substance include immunogenicity risk for certain routes of administration and problems with peptide-related impurities and characterization of the active ingredient [16].

Regulatory and Anti-Doping Status

BPC-157 is not approved in any country FDA searched, and there is no US Pharmacopeia or National Formulary monograph for it [1]. It is not on FDA's list of bulk substances that can be used in compounding, and it is not in the category FDA generally does not act against compounders for. It sits in the separate table of substances nominated but withdrawn, and the page still carries FDA's concerns: possible immunogenicity, peptide impurity and characterization problems, and no or only limited safety information [16][17]. Removal from the significant-risk category was not a finding of safety [16].

On July 23, 2026, FDA's Pharmacy Compounding Advisory Committee voted in favor of adding BPC-157 to the compounding bulks list against FDA staff's recommendation; news reports give the vote as 8 to 6 with one abstention. That vote is advice only; listing requires formal rulemaking [18][8]. On October 28, 2026, HHS filed a draft enforcement-discretion policy naming six peptides including BPC-157, with conditions such as BPC-157 acetate only, subcutaneous, intramuscular, oral or topical routes, a single active ingredient, bulk substance from an FDA-registered manufacturer with a valid certificate of analysis, a patient-specific prescription, and reporting of serious adverse events to MedWatch [7][8]. The notice states it does not establish rights for any person and is not binding on HHS or the public [8].

AOD-9604 appears in the same nominated-but-withdrawn table, with FDA noting limited safety information and serious adverse events of unclear causality [16]. It is in none of the three categories on FDA's list for state-licensed pharmacies and physicians, and it is not on FDA's list for outsourcing facilities [17][19]. It is not among the six peptides in the HHS draft policy and was not on the July 2026 advisory committee agenda [7][18]. FDA's GRAS Notice Inventory contains no AOD-9604 entry, so there is no FDA no-questions letter for it [20].

WADA names BPC-157 in S0 (non-approved substances) and AOD-9604 and hGH 176-191 in S2.2.3 (growth hormone fragments). Both are prohibited at all times, in and out of competition, and both are on the 2026 List and remain on the 2027 List [6][21].